What’s behind all the M&A deals in pharma?
As far as M&A deals go, 2019 has started off with a boom.
Pfizer to combine off-patent drug business with Mylan
Pfizer has agreed to merge its off-patent drugs business with generic drugmaker Mylan.
Pfizer has agreed to merge its off-patent drugs business with generic drugmaker Mylan.
Merck to build new plant in N.C.
Merck will invest some $680M in new manufacturing space and expanded packaging space to support its HPV vaccine Gardisil.
New painkiller destined for greatness may only get limited FDA nod
One of the buzziest new drugs has been Pfizer and Eli Lilly’s tanezumab, which works by selectively targeting, binding to and blocking nerve growth factor.
Vertex names new CEO
Vertex announced that its chief medical officernwill take over as president and chief executive